1-({2-isopropyl-1-[4-(trifluoromethoxy)phenyl]-1H-benzimidazol-5-yl}carbonyl)-3-[5-(trifluoromethyl)pyridin-3-yl]pyrrolidin-3-ol | 1225214-50-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-({2-isopropyl-1-[4-(trifluoromethoxy)phenyl]-1H-benzimidazol-5-yl}carbonyl)-3-[5-(trifluoromethyl)pyridin-3-yl]pyrrolidin-3-ol
• 英文别名: [3-Hydroxy-3-[5-(trifluoromethyl)pyridin-3-yl]pyrrolidin-1-yl]-[2-propan-2-yl-1-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methanone
• CAS: 1225214-50-5
• 化学式: C₂₈H₂₄F₆N₄O₃
• 分子量: 578.514
• InChiKey: ZQERXZYGIWMFRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  41
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  80.5
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• [EN] BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES<br/>[FR] BENZIMIDAZOLE ET AZA-BENZIMIDAZOLE CARBOXAMIDES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010051245A1

  公开（公告）日：2010-05-06

  This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.

  这项发明提供了化合物I的公式，这些化合物是PAFR拮抗剂：I及其药用盐。这些化合物可用于治疗PAF介导的疾病，并可用于治疗动脉粥样硬化并预防或减少动脉粥样硬化疾病事件的风险的方法。这些化合物还可用于治疗或缓解疼痛，例如炎症性疼痛和/或伤害性疼痛，并用于治疗或缓解自身免疫和/或炎症性疾病等其他疾病。
• BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2358202A1

  公开（公告）日：2011-08-24
• PIPERIDINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2536710A2

  公开（公告）日：2012-12-26
• US8470819B2
  申请人：——

  公开号：US8470819B2

  公开（公告）日：2013-06-25
• [EN] PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA PIPÉRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011101304A2

  公开（公告）日：2011-08-25

  The invention relates to compounds of formula (I). Hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; hetaryl II is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, O or N, wherein at least one ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen, or halogen; R2 is halogen, lower alkyl, lower alkoxy, hydroxy, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or benzo[1,3]dioxolyl, or is -(CHR)p-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, S(O)2-lower alkyl, cyano, nitro, lower alkoxy substituted by halogen, dimethylamino, -(CH2)P-NHC(O)O-Iower alkyl, or lower alkyl substituted by halogen, and R is hydrogen, halogen, hydroxy or lower alkoxy, or is cycloalkenyl or cycloalkyl, optionally substituted by hydroxy or lower alkyl substituted by halogen, or is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, which is optionally substituted by halogen, lower alkyl, lower alkoxy or dimethylamino, or is O-phenyl, optionally substituted by halogen, or is heterocycloalkyl, optionally substituted by halogen, hydroxy, lower alkyl substituted by halogen or C(O)O-lower alkyl; R3 is hydrogen, lower alkyl, cyano or phenyl; R4 is lower alkoxy, lower alkyl or halogen; p is 0 or 1; n is 0, 1 or 2; if n is 2 then R4 may be the same or different; m is 0, 1 or 2; if m is 2 then R1 may be the same or different; o is 0, 1, 2 or 3, if o is 2 or 3 then R2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The compounds of formula (I) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.